Primary Immune Deficiency (PID) - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 68 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Primary Immune Deficiency (PID) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Primary Immune Deficiency (PID) - Pipeline Review, H2 2014', provides an overview of the Primary Immune Deficiency (PID)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Primary Immune Deficiency (PID), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Primary Immune Deficiency (PID) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Primary Immune Deficiency (PID)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Primary Immune Deficiency (PID) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Primary Immune Deficiency (PID) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Primary Immune Deficiency (PID) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Primary Immune Deficiency (PID)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Primary Immune Deficiency (PID) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Primary Immune Deficiency (PID) Overview 8
Therapeutics Development 9
Pipeline Products for Primary Immune Deficiency (PID) - Overview 9
Pipeline Products for Primary Immune Deficiency (PID) - Comparative Analysis 10
Primary Immune Deficiency (PID) - Therapeutics under Development by Companies 11
Primary Immune Deficiency (PID) - Therapeutics under Investigation by Universities/Institutes 12
Primary Immune Deficiency (PID) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Primary Immune Deficiency (PID) - Products under Development by Companies 16
Primary Immune Deficiency (PID) - Products under Investigation by Universities/Institutes 17
Primary Immune Deficiency (PID) - Companies Involved in Therapeutics Development 18
ADMA Biologics, Inc. 18
Baxter International Inc. 19
Genethon 20
GlaxoSmithKline plc 21
Green Cross Corporation 22
ProMetic Life Sciences Inc. 23
Sangamo BioSciences, Inc. 24
Sanofi 25
Primary Immune Deficiency (PID) - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
(immune globulin (human) + hyaluronidase (recombinant)) - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
GC-1112 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Gene Therapy for Severe Combined Immune Deficiency - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Gene Therapy for X-Linked SCID - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Gene Therapy to Activate Artemis for Radiosensitive Severe Combined Immunodeficiency - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
GSK-2696273 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
immune globulin (human) - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
immune globulin (human) - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
OT-81 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
plerixafor - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
RI-002 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Stem Cell Therapy to Activate Adenosine Deaminase for Severe Combined Immune Deficiency - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Stem Cell Therapy to Activate Adenosine Deaminase for Severe Combined Immune Deficiency - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Stem Cell Therapy to Activate IL-2 Gamma Receptor for SCID-X1 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Primary Immune Deficiency (PID) - Recent Pipeline Updates 53
Primary Immune Deficiency (PID) - Dormant Projects 58
Primary Immune Deficiency (PID) - Product Development Milestones 59
Featured News & Press Releases 59
Dec 03, 2014: ADMA Biologics Announces Positive Top-Line Phase III Data for Primary Immune Deficiency Disease (PIDD) Patients 59
Oct 20, 2014: Baxter Launches HYQVIA in the United States for Adult Patients with Primary Immunodeficiency 60
Sep 12, 2014: FDA Approves Baxter's HYQVIA for Treatment of Adults with Primary Immunodeficiency 61
Jul 31, 2014: FDA Advisory Committee Panel Provides Favorable Recommendation on Baxter's HyQvia for Primary Immunodeficiency 61
May 21, 2014: Baxter Provides U.S. Regulatory Update on HyQvia, Its Investigational Subcutaneous Treatment for Primary Immunodeficiency 62
Apr 03, 2014: ADMA Biologics to Present Data at the 2014 Clinical Immunology Society Meeting 63
Dec 02, 2013: Baxter Submits Amended BLA to U.S. FDA for HyQvia for Primary Immunodeficiency 63
Nov 04, 2013: ADMA Biologics Completes Enrollment of Phase III Study for RI-002 64
May 21, 2013: Baxter Receives Marketing Authorization For HyQvia In EU 65
Mar 22, 2013: Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies 65
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 68
Disclaimer 68

List of Tables
Number of Products under Development for Primary Immune Deficiency (PID), H2 2014 9
Number of Products under Development for Primary Immune Deficiency (PID) - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Products under Investigation by Universities/Institutes, H2 2014 17
Primary Immune Deficiency (PID) - Pipeline by ADMA Biologics, Inc., H2 2014 18
Primary Immune Deficiency (PID) - Pipeline by Baxter International Inc., H2 2014 19
Primary Immune Deficiency (PID) - Pipeline by Genethon, H2 2014 20
Primary Immune Deficiency (PID) - Pipeline by GlaxoSmithKline plc, H2 2014 21
Primary Immune Deficiency (PID) - Pipeline by Green Cross Corporation, H2 2014 22
Primary Immune Deficiency (PID) - Pipeline by ProMetic Life Sciences Inc., H2 2014 23
Primary Immune Deficiency (PID) - Pipeline by Sangamo BioSciences, Inc., H2 2014 24
Primary Immune Deficiency (PID) - Pipeline by Sanofi, H2 2014 25
Assessment by Monotherapy Products, H2 2014 26
Assessment by Combination Products, H2 2014 27
Number of Products by Stage and Target, H2 2014 29
Number of Products by Stage and Mechanism of Action, H2 2014 31
Number of Products by Stage and Route of Administration, H2 2014 33
Number of Products by Stage and Molecule Type, H2 2014 35
Primary Immune Deficiency (PID) Therapeutics - Recent Pipeline Updates, H2 2014 53
Primary Immune Deficiency (PID) - Dormant Projects, H2 2014 58